News & Events

print version
'News & Events' image



Leeds Microbubble Symposium July 14th-July 15th 2014, Weetwood Hall, Leeds UK

Angiotox Researcher Dr. Ian Miller ( Royal College of Surgeons in Ireland) was recently invited to speak at the Annual Leeds Microbubble symposium, Leeds, UK. Dr Miller presented work ongoing within the Angiotox project pertaining to the development of pre-clinical models which can be implemented to validate predictive Systems Biology (SB) tools under development by the team at the Royal College of Surgeons in Ireland, Centre for Systems Medicine. Dr Miller's research seeks to uniquely implement contrast-enhanced (microbubble) ultrasound imaging datasets in the elucidation of SB tools. His Talk entitled "Assessment of Bevacizumab Mechanism of Action in mCRC In Vivomodels Using Contrast Enhanced Ultrasound Imaging" was well received by a specialist ultrasound audience.

NYAS Angiogenesis 2014 June 19th- June 20th New York City, USA

AngioTox Fellow Dr. Ian Miller was recently invited to speak at the prestigious New York Academy of Science (NYAS) Angiogenesis 2014 meeting. His talk entitled Metabolic PET Imaging Approaches as Early Biomarkers of Cardiac Toxicity Following Treatment with the Tyrosine Kinase Inhibitor Sunitinib was chosen as a "Hot Topic" for discussion at the meeting. During the symposium work being performed within Angiotox was highlighted as " an important but oft neglected area in angiogenesis inhibitor research

EMIM June 2014

On the 6th of June, Dr. Ian Miller, Marie Curie Fellow delivered an oral presentation on the work of the RCSI laboratory on the cardiotoxicity of angiogenesis Inhibitor Sunitinib at the European Molecular Imaging Meeting held in Antwerp.



Award for Best Poster

Marie Curie Fellow Dr Ian Miller recently presented a poster on his work in AngioTox, at the Irish Association for Cancer Research (IACR) Annual Meeting ( 28th Feb 2014) in Galway, Ireland. The poster was entitled 'Metabolic Pet Imaging Approaches as Early Biomarkers of Cardiotoxicity Following Treatment with the Tyrosine Kinase Inhibitor Sunitinib'. Dr. Miller was awarded a prize for Best Poster at the Meeting



RCSI Research Day 2014

Dr Ian Miller accepting first prize for his post in the category of Early Career Investigators on Research Day at The Royal College of Surgeons in Ireland








 ANGIOTOX in the Classroom

AngioTox fellow Dr Alice O'Farrell (pictured above) recently hosted a visit at RCSI for 5th year students from St Mary's school in Baldoyle. Dr O'Farrell presented a talk focusing on her background and route into research science, information on some aspects of the AngioTox project and an introduction to non-invasive imaging and its positive role in preclinical imaging.



Marie Curie Fellow Dr Ian Miller (pictured above) also hosted a visit from 5th & 6th year students of a local Dublin secondary school to the RCSI. Dr Miller presented a talk about life as a Research Scientist and explaining the importance of research and science.

The 5th International Angiogenesis Conference, Amsterdam, March 2014

Marie Curie Fellows Dr Ian Miller, Dr. Alice O Farrell, Dr Monika Jarzabek and Dr. David Murray recently presented a poster on their work in AngioTox, at the 5th International Angiogenesis Conference in VUMC in Amsterdam (March 12th-14th 2014). The poster was entitled 'Metabolic Pet Imaging Approaches as Early Biomarkers of Cardiotoxicity Following Treatment with the Tyrosine Kinase Inhibitor Sunitinib'.



 AngioTox Fellow presents at RCSI Mini Med Lecture Series (27th February 2014)

 Dr David Murray recently presented an interesting and informative lecture entitled 'Tackling Cancer by Targeting Tumour Blood Vessels' as part of the RCI Mini Med Lecture Series for 2014. The RCSI MiniMed Open Lecture Series are informative health lectures open free of charge to the public. To watch this lecture, please see:




The AngioTox consortium was delighted when AngioTox partner Genentech/ Roche sponsored the International Angiogenesis Biomarker Symposium, which took place in VU Medical Centre, Amsterdam on March 14th as part of the 5th International Meeting on Angiogenesis.

The Biomarker Session was chaired by AngioTox co-ordinators Dr Annette Byrne (Royal College of Surgeons in Ireland) & Prof Henk Verheul (VU Medical Centre Amsterdam). Both Dr Byrne & Prof Verheul delivered plenary talks during the Session, along with Dr Carlos Bais from Genentech /Roche, and additional expert speakers from the Angiogenesis Biomarker field. Several AngioTox Marie Curie Fellows presented posters at the Meeting, providing updates on their research findings to date.





AngioTox Marie Curie Fellow Dr Alice O'Farrell (pictured below) recently presented a poster at the RCSI Research day entitled 'Mechanistic interrogation of Cardiac and Vascular Toxicities associated with the Receptor Tyrosine Kinase Inhibitor Sunitinib: Investigation of Novel Safety Biomarkers of Cardiotoxicity '



'PRIZE FOR BEST POSTER' Award -MMI Education & Training Scientific Meeting, Dublin 2013

Dr O'Farrell was awarded 'Prize for Best Poster' at the MMI Education & Training Scientific Meeting which was held at Trinity College Dublin in March 2013




















Oct 2012, San Diego USA

Project co-ordinator Dr Annette Byrne (pictured right) recently presented a new ANGIOTOX related ANGIOPREDICT (FP7 Health Award) initiative to a highly specialist audience at the Angiogenesis Foundation's 10th International M. Judah Folkman Conference: New Frontiers in Therapeutic Development, San Diego USA. Dr Byrne was invited to present at this prestigious event by the Foundation's President and Medical Director William W. Li MD. Following the Angiogenesis Biomarker Session on Day 2 of the meeting, Dr Li personally congratulated Dr Byrne and team on the novel integrated multi-disciplinary paradigm to be undertaken, commenting that the future of angiogenesis inhibitor biomarker discovery likely lay in such an approach.


AngioTox Consortium holds Year 2 Planning Meeting and Mid Term Review Meeting, Dublin (June 2012)

The AngioTox Consortium met in June for a successful Year 2 Planning Meeting. It was very beneficial to get together to discuss the progress made since the Project began and to ensure we are on track for another 2 successful years of working together.

In the same week, the Consortium met with our EU Project Officer and an External Evaluator for our Mid Term Review Meeting (pictured right)


Irish Association for Cancer Research Meeting, Belfast (March 2012)

Angiotox Co-ordinator Dr. Annette Byrne delivered a lecture at the 'Angiogenesis & Inflammation' session, entitled 'Mechanisms of Toxicity associated with Clinically Approved Angiogenisis Inhibitors'

Dr. Rhys Evans also presented a poster at the 'Oral Poster Presentations'


14th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions conference in La Jolla, San Diego, California (February 2012)

Dr. Rhys Evans (Pictured below right) recently presented a poster at this conference entitled 'Cardiovascular Toxicities associated with the Receptor Tyrosine Kinase Inhibitor Sunitinib:

A Multi-Modality Molecular Imaging (MMI) approach' . Dr Evan's poster received a high level of interest from meeting participants and presenters alike. In

Dr. Rhys Evans

particular several attendees commented on the successful Angiotox approach towards ' reverse translation' of clinical toxicity findings as manifested by prolonged increases in blood pressure observed in animal models. The MMI approach taken was further commended as a convincing approach towards the early detection of angiogenesis inhibitor toxicities.


AngioTox Fellow Chosen to Participate in EuroBioimaging Iniative (January 2012)

Dr Alice O'Farrell (AngioTox Marie Curie Fellow, RCSI) has recently been successful in an application to participate in the EuroBioimaging ( proof-of-concept initiative. The EuroBioimaging training initiative is a competitive, peer reviewed platform to provide unique training to Fellows and trainees in the molecular imaging space. Dr O'Farrell's application was chosen from more than two hundred submitted proposals across Europe. The 8 week secondment is to take place at the National PET centre in Turku, Finland later in 2012. Currently at the Royal College of Surgeons, the effect of treatment with angiogenesis inhibitors on cardiac function is being investigated using novel radioisotope imaging strategies. The work that is proposed for the course of the study period will greatly enhance ongoing investigations and will further interrogate novel PET and MR imaging approaches for predictive value in identifying subjects at risk of cardiotoxicity following angiogenesis inhibitor treatment. In addition, Dr O'Farrell will have the opportunity to work with experts in the Cardiotoxicity field and gain valuable knowledge and hands-on experience of state of the art non-invasive imaging methods.


New collaboration formed with Nuclear Imaging Department of Universite de Sherbrooke.

RCSI and UCD have begun a collaboration with the laboratory of imaging expert Professor Roger Lecomte to investigate cardiovascular toxicities associated with angiogenesis inhibitors using novel and established PET tracers.


AngioTox first year meeting takes place at VUMC (September 2011)

Representatives from each of the consortium members were present at the year one meeting to discuss the results obtained from the previous years work and establish what would occur over the next 12 months.

 AngioTox employee presents at Marie Curie conference in Warsaw (September 2011)

AngioTox was represented at the recent Marie Curie conference as Rhys Evans presented a poster titled: Mechanistic Assessment of Cardiovascular Toxicities Associated with the Multi-targeted Tyrosine Kinase Inhibitor Sunitinib. This detailed results obtained from previous imaging studies and the collaboration with the Professor Roger Lecomte group.

AC O'Farrell1, R Evans1, E Conroy2, L Shiels1, M Alamanou3, S Gascon4, J Rousseau4, W Gallagher2,3, M Cary5, R Lecomte4 and AT Byrne1

1Royal College of Surgeons in Ireland, 2University College Dublin, 3Oncomark Ltd, 4Université de Sherbrooke, 5Pathology Experts GmbH.